Objective-The thrombolytic therapy drug, Reteplase, is a domain deletion mutant of tissue plasminogen activator (tPA), comprising the kringle 2 and protease (K2P) domains. Some kringle domains of hemostatic proteins are antiangiogenic and promote apoptosis. The objective of this study was to investigate whether K2P is an angiogenesis inhibitor because of the presence of kringle 2. Methods and Results-K2P inhibited basic fibroblast growth factor-induced human endothelial cell proliferation and migration. Inhibition was not dependent on the protease activity of K2P because similar results were obtained with catalytically inactivated K2P. Purification of the kringle 2 domain derived from elastase cleavage of K2P at the Arg 275 -Ile 276 bond revealed that inhibition was mediated by this domain. In addition, K2P inhibited angiogenesis in vivo and increased endothelial cell apoptosis. Conclusions-Wound healing and angiogenesis are severely compromised by K2P. These data provide new mechanistic insights into the bleeding complications observed in some patients while undergoing thrombolytic therapy with this drug. In addition, we identify the kringle 2 domain of tPA as a novel target for antiangiogenic therapy. Key Words: antiangiogenesis Ⅲ reteplase Ⅲ kringle 2 Ⅲ endothelial cells Ⅲ wound healing T issue plasminogen activator (tPA) is a serine protease that activates fibrinolysis through the conversion of plasminogen to plasmin. Plasmin, in turn, degrades fibrin in the vasculature during clot dissolution and wound healing. 1 tPA is expressed in a variety of cell types including endothelial cells 2 and tumor cells. 3,4 It is a multidomain protein that consists of a finger domain, an epidermal growth factor-like domain, 2 kringle modules, and a protease domain. Its widespread use for treating thrombosis during acute myocardial infarction has led to the development of tPA derivatives with improved pharmacokinetic properties. 5 One of these is the domain deletion mutant comprising just the kringle 2 and protease domains (K2P) of tPA. 6 Kringles are triple-loop structures of Ϸ80 amino acids. 7 Recent studies have shown that isolated kringle domains of proteins involved in the hemostatic system are antiangiogenic. These include plasminogen, which has 5 kringle domains, 8 hepatocyte growth factor, which has 4, 9 prothrombin, which has 2 kringles, 10 and urokinase plasminogen activator (uPA), which has just 1. 11 Angiostatin, consisting of kringles 1 to 4 of plasminogen, was first shown to inhibit basic fibroblast growth factor (bFGF)-mediated endothelial cell proliferation and tumor angiogenesis. 12 Further studies have shown that the individual plasminogen kringles have varying efficacy on endothelial cells. Kringles 1 to 3 and kringle 5 inhibit endothelial cell growth, 13,14 whereas the kringle 4 domain is a weaker inhibitor of cell growth but significantly blocks endothelial cell migration. 13,15 Angiostatin-specific binding sites have been identified on endothelial cells, including ATP-synthase and angiomotin, 16,17 and i...